Five years of large-scale dhfr and dhps mutation surveillance following the phased implementation of artesunate plus sulfadoxine-pyrimethamine in Maputo Province, Southern Mozambique.

Accumulation of mutations in dihydrofolate reductase (dhfr) and dihydropteroate synthetase (dhps) is strongly associated with sulfadoxine-pyrimethamine (SP) treatment failure. Routine surveillance for these resistance markers was conducted annually at 26 sentinel sites in Maputo Province, Mozambique, before and after the phased deployment of artesunate plus SP (AS-SP), with 15,758 children sampled between 2004 and 2008. Mean asexual parasite prevalence, polymerase chain reaction (PCR) corrected, decreased from 44.2% in 2004 to 3.8% in 2008 (P < 0.0001). Among the 2,012 PCR-confirmed falciparum samples, the dhfr triple mutation remained close to fixation, whereas both dhps double and dhfr/dhps "quintuple" mutations increased from 11.0% in 2004, to 75.0% by 2008 (P < 0.0001). Adding artesunate to SP did not retard the spread of SP-resistant parasites. The high "quintuple" mutation prevalence suggests a limited useful therapeutic lifespan of AS-SP for treating uncomplicated malaria, and may curb efficacy of SP-monotherapy for intermittent preventive treatment in Mozambique.

[1]  K. Silamut,et al.  Artemisinin resistance in Plasmodium falciparum malaria. , 2009, The New England journal of medicine.

[2]  K. Barnes,et al.  Efficacy of sulphadoxine-pyrimethamine with or without artesunate for the treatment of uncomplicated Plasmodium falciparum malaria in southern Mozambique: a randomized controlled trial , 2009, Malaria Journal.

[3]  M. Fukuda,et al.  Evidence of artemisinin-resistant malaria in western Cambodia. , 2008, The New England journal of medicine.

[4]  S. Meshnick,et al.  Molecular Surveillance for Multidrug-Resistant Plasmodium falciparum, Cambodia , 2008, Emerging infectious diseases.

[5]  M. Alifrangis,et al.  Rapid increase of Plasmodium falciparum dhfr/dhps resistant haplotypes, after the adoption of sulphadoxine-pyrimethamine as first line treatment in 2002, in southern Mozambique , 2008, Malaria Journal.

[6]  D. Durrheim,et al.  Increased gametocytemia after treatment: an early parasitological indicator of emerging sulfadoxine-pyrimethamine resistance in falciparum malaria. , 2008, The Journal of infectious diseases.

[7]  M. Molyneux,et al.  Sulfadoxine-Pyrimethamine–Based Combinations for Malaria: A Randomised Blinded Trial to Compare Efficacy, Safety and Selection of Resistance in Malawi , 2008, PloS one.

[8]  I. Kleinschmidt,et al.  Differential effect of regional drug pressure on dihydrofolate reductase and dihydropteroate synthetase mutations in southern Mozambique. , 2008, The American journal of tropical medicine and hygiene.

[9]  D. Sullivan,et al.  High prevalence of molecular markers for resistance to chloroquine and pyrimethamine in Plasmodium falciparum from Zimbabwe , 2007, Parasitology Research.

[10]  P. Rosenthal,et al.  Comparison of HRP2- and pLDH-based rapid diagnostic tests for malaria with longitudinal follow-up in Kampala, Uganda. , 2007, The American journal of tropical medicine and hygiene.

[11]  M. Molyneux,et al.  Molecular surveillance for drug-resistant Plasmodiumfalciparum malaria in Malawi. , 2007, Acta tropica.

[12]  Francesca Little,et al.  Sulfadoxine‐pyrimethamine pharmacokinetics in malaria: Pediatric dosing implications , 2006, Clinical pharmacology and therapeutics.

[13]  N. Horton.  Multilevel and Longitudinal Modeling Using Stata , 2006 .

[14]  David L Smith,et al.  Potential Impact of Intermittent Preventive Treatment (IPT) on Spread of Drug-Resistant Malaria , 2006, PLoS medicine.

[15]  P. Olliaro.  Drug resistance hampers our capacity to roll back malaria. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  D. Durrheim,et al.  Therapeutic efficacy of sulfadoxine-pyrimethamine for Plasmodium falciparum malaria. , 2005, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[17]  C. Drakeley,et al.  Reduction of Malaria Transmission to Anopheles Mosquitoes with a Six-Dose Regimen of Co-Artemether , 2005, PLoS medicine.

[18]  S. Hay,et al.  The global distribution of clinical episodes of Plasmodium falciparum malaria , 2005, Nature.

[19]  E. van Marck,et al.  Two mutations in dihydrofolate reductase combined with one in the dihydropteroate synthase gene predict sulphadoxine-pyrimethamine parasitological failure in Ugandan children with uncomplicated falciparum malaria. , 2004, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[20]  François Nosten,et al.  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number , 2004, The Lancet.

[21]  P Garner,et al.  Artesunate combinations for treatment of malaria: meta-analysis , 2004, The Lancet.

[22]  C. Karema,et al.  Efficacy of amodiaquine alone and combined with sulfadoxine-pyrimethamine and of sulfadoxine pyrimethamine combined with artesunate. , 2003, The American journal of tropical medicine and hygiene.

[23]  B. Sharp,et al.  Antifolate antimalarial resistance in southeast Africa: a population-based analysis , 2003, The Lancet.

[24]  A. Kaneko,et al.  High prevalence of quintuple mutant dhps/dhfr genes in Plasmodium falciparum infections seven years after introduction of sulfadoxine and pyrimethamine as first line treatment in Malawi. , 2003, Acta tropica.

[25]  P. Rosenthal,et al.  Sulfadoxine/pyrimethamine alone or with amodiaquine or artesunate for treatment of uncomplicated malaria: a longitudinal randomised trial , 2002, The Lancet.

[26]  C. Drakeley,et al.  Artesunate reduces but does not prevent posttreatment transmission of Plasmodium falciparum to Anopheles gambiae. , 2001, The Journal of infectious diseases.

[27]  R. Price,et al.  Plasmodium falciparum antimalarial drug susceptibility on the north-western border of Thailand during five years of extensive use of artesunate-mefloquine. , 2000, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[28]  Richard N. Price,et al.  Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study , 2000, The Lancet.

[29]  O. Doumbo,et al.  Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance. , 1997, The Journal of infectious diseases.

[30]  W. Jarra,et al.  High sensitivity of detection of human malaria parasites by the use of nested polymerase chain reaction. , 1993, Molecular and biochemical parasitology.

[31]  S. Kyes,et al.  PCR and strain identification in Plasmodium falciparum. , 1993, Parasitology today.

[32]  C. Dolea,et al.  World Health Organization , 1949, International Organization.

[33]  Organización Mundial de la Salud.  Guidelines for the treatment of malaria , 2010 .

[34]  Rajendra Maharaj,et al.  Seven years of regional malaria control collaboration--Mozambique, South Africa, and Swaziland. , 2007, The American journal of tropical medicine and hygiene.

[35]  R. Price,et al.  Intrahost selection of Plasmodium falciparum pfmdr1 alleles after antimalarial treatment on the northwestern border of Thailand. , 2007, The Journal of infectious diseases.

[36]  Weltgesundheitsorganisation.  World malaria report , 2005 .

[37]  R. Snow,et al.  Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria , 2003 .

[38]  W. Watkins,et al.  Treatment of Plasmodium falciparum malaria with pyrimethamine-sulfadoxine: selective pressure for resistance is a function of long elimination half-life. , 1993, Transactions of the Royal Society of Tropical Medicine and Hygiene.